Nicholas Alexander Vitanza MD
Pediatric Neuro-Oncology
Pediatric Neuro-Oncologist and Translational Scientist at Seattle Children's
Join to View Full Profile
4800 Sand Point Way NE# MB8Seattle, WA 98105
Phone+1 845-559-3679
Dr. Vitanza is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Pediatric Neuro-Oncology, 2014 - 2016
NYU Grossman School of MedicineFellowship, Pediatric Hematology/Oncology, 2011 - 2014
Stony Brook Medicine/University HospitalResidency, Pediatrics, 2008 - 2011
American University of the Caribbean School of MedicineClass of 2008
Certifications & Licensure
CA State Medical License 2014 - Present
WA State Medical License 2016 - 2027
ID State Medical License 2021 - 2025
AK State Medical License 2021 - 2022
NY State Medical License 2011 - 2019
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Young Investigator Travel Stipend Award American Society of Pediatric Hematology/Oncology, 2014
- Research Training Award for Fellows American Society of Hematology, 2013
Clinical Trials
- ONC201 in Pediatric H3 K27M Gliomas Start of enrollment: 2018 Jan 25
- HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors Start of enrollment: 2018 Jul 26
Publications & Presentations
PubMed
- Locoregional Infusion of EGFR806-CAR T Cells for Recurrent or Refractory Pediatric CNS Tumors: Results of the Completed BrainChild02 Phase 1 Clinical Trial.Juliane Gust, Bonnie L Cole, Rebecca Ronsley, Ashley L Wilson, Kristy Seidel
Neuro-Oncology. 2025-03-12 - 1 citationsIntracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial.Nicholas A Vitanza, Rebecca Ronsley, Michelle Choe, Kristy Seidel, Wenjun Huang
Nature Medicine. 2025-03-01 - 2 citationsSTRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors.Navin Pinto, Catherine M Albert, Mallory R Taylor, Heidi B Ullom, Ashley L Wilson
Journal of Clinical Oncology. 2024-12-10
Press Mentions
Experimental Treatment Borrowed from Blood Cancer Shows Promise for Pediatric Brain TumorsMarch 19th, 2025- Novel Approaches to Malignant Brain Tumor Treatment Aim to Overcome Familiar ChallengesJanuary 27th, 2022
- AeroPress Grants Cancer Research Award to Dr. Nicholas VitanzaMarch 24th, 2021
- Join now to see all
Grant Support
- Research Training Award for FellowsAmerican Society of Hematology2013–2014
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
